Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 May;59(5):391-8.
doi: 10.1007/s00011-009-0117-4. Epub 2009 Nov 27.

The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber

Affiliations
Clinical Trial

The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber

Friedrich Horak et al. Inflamm Res. 2010 May.

Abstract

Objective and design: This double-blind cross-over study compared the potential of bilastine, cetirizine, and fexofenadine to relieve the symptoms of allergic rhinitis.

Subjects and methods: Seventy-five allergic volunteers were challenged with grass pollen in the Vienna Challenge Chamber (VCC) on two consecutive days of allergen provocation; 6 h on day 1 and 4 h day 2. Bilastine 20 mg, cetirizine 10 mg, fexofenadine 120 mg, or placebo were taken orally 2 h after the start of provocation on day 1 only. Total nasal symptom scores, the global symptom scores, nasal secretions, and eye symptoms were assessed on both day 1 and day 2.

Results and conclusions: Bilastine had a rapid onset of action, within 1 h, and a long duration of action, greater than 26 h. Cetirizine was similar. Fexofenadine was similar on day 1 but less effective on day 2, indicating a shorter duration of action. Bilastine, like cetirizine and fexofenadine, was safe and well tolerated in this study.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Allergy Clin Immunol. 2002 Jun;109(6):956-61 - PubMed
    1. Drug Metab Dispos. 2008 Jan;36(1):61-4 - PubMed
    1. Allergy. 2008 Apr;63 Suppl 86:8-160 - PubMed
    1. Drugs R D. 2005;6(6):371-84 - PubMed
    1. Clin Exp Allergy. 2004 Jun;34(6):958-64 - PubMed

Publication types

MeSH terms